You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

List of Excipients in API BEXAROTENE


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing BEXAROTENE

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Bausch Health US LLC TARGRETIN bexarotene 0187-5525 ALCOHOL
Bausch Health US LLC TARGRETIN bexarotene 0187-5525 BUTYLATED HYDROXYTOLUENE
Bausch Health US LLC TARGRETIN bexarotene 0187-5525 HYDROXYPROPYL CELLULOSE
Bausch Health US LLC TARGRETIN bexarotene 0187-5525 POLYETHYLENE GLYCOL 400
Bausch Health US LLC TARGRETIN bexarotene 0187-5526 1,4-SORBITAN
Bausch Health US LLC TARGRETIN bexarotene 0187-5526 BUTYLATED HYDROXYANISOLE
Bausch Health US LLC TARGRETIN bexarotene 0187-5526 CROSPOVIDONE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Get Started Free

Excipients in ANDA-approved (generic) drugs containing BEXAROTENE

Company Ingredient NDC Excipient
Hikma Pharmaceuticals USA Inc bexarotene 0054-0399 BUTYLATED HYDROXYANISOLE
Hikma Pharmaceuticals USA Inc bexarotene 0054-0399 FERROSOFERRIC OXIDE
Hikma Pharmaceuticals USA Inc bexarotene 0054-0399 GELATIN
Hikma Pharmaceuticals USA Inc bexarotene 0054-0399 GLYCERIN
Hikma Pharmaceuticals USA Inc bexarotene 0054-0399 HYPROMELLOSE
Hikma Pharmaceuticals USA Inc bexarotene 0054-0399 ISOPROPYL ALCOHOL
Hikma Pharmaceuticals USA Inc bexarotene 0054-0399 MANNITOL
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Get Started Free

Detailed excipient profiles for BEXAROTENE

Excipient focus: 1,4-SORBITAN

Excipient focus: ALCOHOL

Excipient focus: AMMONIA

Excipient focus: BUTYL ALCOHOL

Excipient focus: BUTYLATED HYDROXYANISOLE

Excipient focus: BUTYLATED HYDROXYTOLUENE

Excipient focus: CROSPOVIDONE

Excipient focus: DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER

BEXAROTENE drug variants not containing DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER

Company Ingredient NDC
Hikma Pharmaceuticals USA Inc bexarotene 0054-0399
Bausch Health US LLC bexarotene 0187-5525
Bausch Health US LLC bexarotene 0187-5526
Mylan Pharmaceuticals Inc bexarotene 0378-6955
Actavis Pharma Inc bexarotene 0591-2832
Upsher-Smith Laboratories Inc bexarotene 0832-0285
Camber Pharmaceuticals Inc bexarotene 31722-380
>Company >Ingredient >NDC

Subscribe to access the full database, or Get Started Free

Excipient focus: FD&C BLUE NO. 1

Excipient focus: FD&C RED NO. 40

Excipient focus: FD&C YELLOW NO. 6

Excipient focus: FERROSOFERRIC OXIDE

Excipient focus: GELATIN

Excipient focus: GELATIN HYDROLYZATE

Excipient focus: GELATIN TYPE B BOVINE

Excipient focus: GLYCERIN

Excipient focus: HYDROXYPROPYL CELLULOSE

Excipient focus: HYPROMELLOSE

Excipient focus: HYPROMELLOSE 2910

Excipient focus: ISOPROPYL ALCOHOL

Excipient focus: LECITHIN, SOYBEAN

Excipient focus: MANNITOL

Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES

Excipient focus: NITROGEN

Excipient focus: POLYETHYLENE GLYCOL

Excipient focus: POLYETHYLENE GLYCOL 400

Excipient focus: POLYSORBATE 20

Excipient focus: POLYVINYL ACETATE PHTHALATE

Excipient focus: POVIDONE

Excipient focus: POVIDONE K30

Excipient focus: POVIDONE K90

Excipient focus: PROPYLENE GLYCOL

Excipient focus: SHELLAC

Excipient focus: SORBITAN

Excipient focus: SORBITOL

Excipient focus: SORBITOL SOLUTION

Excipient focus: TITANIUM DIOXIDE

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links